Amnon Cohen
Boston Children's Hospital
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Amnon Cohen.
Journal of Clinical Oncology | 2007
Amnon Cohen; Attilio Rovelli; Domenico Franco Merlo; Maria Teresa Van Lint; Edoardo Lanino; Dorine Bresters; Marcello Ceppi; Vittorio Bocchini; André Tichelli; Gérard Socié
PURPOSE The effects of hematopoietic stem-cell transplantation (HSCT) on thyroid carcinogenesis needs to be determined in a large population. This study evaluates the incidence and the risk factors contributing to secondary thyroid carcinoma (STC) in patients who receive transplantation. PATIENTS AND METHODS We performed a retrospective investigational study, comparing data obtained by means of a two-step questionnaire from the 166 centers who replied, and data reported to the European Group for Blood and Marrow Transplantation (EBMT) registry on their transplantation activity. During the follow-up period (1985 to 2003), 32 instances of STC were found within the EBMT cohort of 68,936 patients who received transplants. These patients were then compared with age- and sex-specific incidence rates in the European population and risk factors for STC were analyzed. RESULTS The standardized incidence ratios (SIRs) of STC in the population who underwent transplantation was 3.26, in comparison with the European population. Multivariate analysis revealed that young age at transplantation was the strongest risk factor for STC (relative risk [RR], 24.61 for age 0 to 10 years; RR, 4.80 for age 11 to 20). Other risk factors were irradiation (RR, 3.44), female sex (RR, 2.79), and chronic graft-versus-host disease (RR, 2.94). Nine patients showed no clinical signs of thyroid illness at diagnosis. Total thyroidectomy and iodine ablation was the standard treatment for the majority of patients, and only one patient died due to STC progression. CONCLUSION Long-term survivors of HSCT are at risk for STCs. These results should promote efforts in screening for early detection and treatment guidelines of secondary thyroid cancer after HSCT, especially in patients who receive transplants during childhood and adolescence.
Bone Marrow Transplantation | 2001
Amnon Cohen; Attilio Rovelli; M T Van Lint; Franco Merlo; Alberto Gaiero; R Mulas; A Balduzzi; P Corti; Cornelio Uderzo; A. Bacigalupo
The aim of this study was to evaluate the incidence and risk factors related to secondary thyroid carcinoma (STC) in patients who have undergone allogeneic BMT during childhood. Data related to the primary hematological disorder and BMT procedure were obtained from the records of 113 patients (42 F; 71 M) who underwent BMT before the age of 18 (median 10.0 years; range 1.7–18.0) and survived more than 3 years after transplant with a median follow-up of 10.1 years (range 3.0–19.0). Sixteen received cranial radiation (CRT) during first-line treatment. Pre-transplant conditioning included TBI in 85 patients, TAI in two, while 26 children did not receive irradiation. The standardized incidence ratio of STC after BMT was significantly higher (P < 0.001) than that of the general population. STC was found in eight patients, 3.1 to 15.7 years after transplant. All received TBI and three also CRT. The Coxs regression analysis, although not statistically significant due to the small study population, showed an increased risk in those who had received a cumulative radiation dose higher than 10 Gy and in those who developed chronic GVHD. Careful follow-up of thyroid status including annual ultrasound examination is recommended for early detection of tumor.Bone Marrow Transplantation (2001) 28, 1125–1128.
Archives of Disease in Childhood | 1996
Amnon Cohen; Attilio Rovelli; M T Van-Lint; Cornelio Uderzo; A Morchio; C Pezzini; G Masera; A. Bacigalupo; C Romano
OBJECTIVE: To determine the impact on final adult height of bone marrow transplantation. METHODS: The final height of 28 long term survivors (18 males; 10 females), allografted before or at the onset of puberty, at a median age of 10.8 years (range 6.3 to 14.6) and who did not receive growth hormone (GH) treatment or other growth promoting agents, was evaluated. Median follow up period after bone marrow transplantation was 7.9 years (range 3.2 to 11.4), and age at the most recent evaluation 18.1 years (range 15.6 to 24.5). Height values were expressed in standard deviation score (SDS) from the mean of the normal population. Height at bone marrow transplantation was compared with final height as well as with parental genetic height. Patients were divided into three groups: severe aplastic anaemia (SAA): three patients given no radiotherapy; leukaemia-total body irradiation (TBI): 14 patients with acute or chronic leukaemia conditioned with chemotherapy and TBI; leukaemia-TBI with previous cranial radiation therapy (CRT): 11 patients. None of the patients had solid tumour. RESULTS: There was a decrease in final height SDS compared to pre-transplantation height SDS (paired t test, p < 0.0001). All patients except one reached an adult height above -2.0 SDS. A significant decrease in height SDS was found in the TBI and the CRT groups (paired t test, p = 0.02 and p = 0.0002, respectively). Whereas height SDS value at the time of transplant was higher than the genetic height SDS, final height SDS values were lower. CONCLUSIONS: Despite the decrease in height SDS found after bone marrow transplantation, 27 of the 28 patients spontaneously achieved what is considered to be a normal height SDS (above -2.0 SDS). This should be taken into account when considering GH treatment in children who underwent bone marrow transplantation for malignant haematological diseases.
Bone Marrow Transplantation | 1999
Amnon Cohen; Thomas Duell; Gérard Socié; M T Van Lint; Melanie Weiss; André Tichelli; Attilio Rovelli; Jane F. Apperley; Per Ljungman; Hans Jochem Kolb
The European Group for Blood and Marrow Transplantation (EBMT) Late-Effects Working Party collected data on patients who survived more than 5 years after BMT. Height at transplant and at the latest follow-up examination were evaluated in 79/258 subjects who were below the age of 15 at BMT. A significant decrease in height-standard deviation score (SDS) was observed in leukemic children conditioned with total body irradiation (TBI) and in those who received both cranial irradiation and TBI. The majority of these patients, however, received single-dose TBI (28/41). A significant decrease in height-SDS was also seen in children who received thoraco-abdominal irradiation suggesting that the deleterious effect of irradiation on growth after BMT is not entirely due to injury to cranial neuroendocrine structures, but also probably due to damage to bone epiphyses, thyroid and gonads. A non-significant decrease in height was observed in children transplanted using chemotherapy alone. Nutritional status, expressed as body-mass index (BMI), was found unchanged in the adult group (n = 158). A significant increase in BMI was observed in the younger patients (n = 88), which parallels the normal increase in BMI observed during childhood. This suggests that on long-term analysis, a good nutritional status is maintained in patients undergoing BMT at any age.
Archives of Disease in Childhood | 1994
Cornelio Uderzo; M T van Lint; Attilio Rovelli; G Weber; M R Castellani; A. Bacigalupo; N Masera; Amnon Cohen
Two children developed papillary thyroid carcinoma after allogeneic bone marrow transplantation (BMT) probably due to radiotherapy during remission and pretransplantation conditioning. Establishing a relationship between the cellular thyroid stimulating hormone (TSH) effect and development of carcinoma in cases with high serum TSH concentrations is difficult. After BMT, patients should be regularly followed up with thyroid ultrasound and, when nodularity is found, fine needle aspiration and/or open biopsy are recommended.
Fetal and Pediatric Pathology | 1993
Massimo Brisigotti; Giovanna Fabbretti; Ferdinando Pesce; Rosanna Gatti; Amnon Cohen; Giancarlo Parenti; Francesco Callea
We report on a case of leprechaunism. In addition to the typical clinical and biochemical features, a bilateral juvenile granulosa cell tumor of the ovaries and cytomegalovirus hepatitis were found. The granulosa cell tumor may result from the mitogenic effect of insulin at high concentration, which acts via a mechanism mediated by insulin-like growth factor I receptors.
Acta Haematologica | 1997
Attilio Rovelli; Amnon Cohen; Cornelio Uderzo; Paolo Dodero; Massimo Brisigotti; Maria Rita Castellani; Cesare Romano
Follicular cell carcinoma (FCC) of the thyroid is rarely found during childhood. We report a 12 1/2-year-old girl with acute lymphoblastic leukemia, who developed rapidly growing FCC of the thyroid, 3 years after bone marrow transplantation. The role of chemotherapy in the induction of such secondary tumors after transplantation is discussed, and a proposal for the approach to these patients is suggested.
Pediatric Transplantation | 2008
Maura Faraci; Giuseppe Morreale; Elio Boeri; Edoardo Lanino; Sandro Dallorso; Giorgio Dini; Francesca Scuderi; Amnon Cohen; Barbara Cappelli
Abstract: CEP is a rare inborn error of porphyrin–heme synthesis. Clinical manifestations can range from mild to severe and include erythrodontia, reddish‐colored urine, and hemolytic anemia that can be mild or severe and may result in splenomegaly. Completely avoiding exposure to the sun is crucial. Attempts to reduce erythropoiesis and to lower circulating porphyrin levels by means of erythrocyte transfusions have been successful in reducing the expression of the disease. However, the complications of a chronic transfusion regimen are potentially severe. Successful bone marrow transplantation has been reported in CEP. We report a case of successful bone marrow transplantation and prolonged follow‐up in an adolescent CEP patient.
Pediatric Transplantation | 2009
Amnon Cohen
In this issue of the journal, Mellouli et al. (1) describe a nine-yr-old boy who developed type-1 diabetes mellitus (DM) three yr after receiving a hematopoietic cell transplant from his HLAidentical sister affected by type-1 DM. This emblematic case launches a debate on the variety of effects that hematopoietic stem cell transplantation (HSCT) has on the immune system and, in particular, on autoimmune conditions. In fact, while HSCT might induce the autoimmune disorder in the recipient as a result of transferring the disease from the affected donor, it could also be used as an innovative tool in the treatment of chronic and debilitating autoimmune and inflammatory diseases resistant to conventional therapy.
Clinical Genetics | 2008
Amnon Cohen; Silvia Zecca; Alessandra Dassori; Monica Pelegrini; Lorenza Parodi; Cesare Romano
We report on Poland sequence observed in two siblings (a girl and a boy) in the same family. This suggests an inheritance pattern consistent with an autosomal recessive or dominant trait transmission with reduced penetrance.